Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $19.8 Million - $26 Million
490,868 New
490,868 $20.4 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $7.5 Million - $8.39 Million
129,613 Added 32.4%
529,613 $30.7 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $25.5 Million - $28.3 Million
400,000 New
400,000 $25.6 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $72,280 - $42.7 Million
-556,000 Reduced 48.1%
600,000 $42.7 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $17.4 Million - $19.2 Million
-240,000 Reduced 17.19%
1,156,000 $89 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $57.1 Million - $68.4 Million
-928,000 Reduced 39.93%
1,396,000 $102 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $1.72 Million - $2 Million
-32,000 Reduced 1.36%
2,324,000 $145 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $40.1 Million - $47 Million
678,000 Added 40.41%
2,356,000 $139 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $11 Million - $12 Million
178,000 Added 11.87%
1,678,000 $112 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $27.5 Million - $31 Million
464,000 Added 44.79%
1,500,000 $94.7 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $2.08 Million - $2.36 Million
36,000 Added 3.6%
1,036,000 $64.3 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $19.3 Million - $22.6 Million
352,000 Added 54.32%
1,000,000 $58.8 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $6.87 Million - $9.98 Million
148,000 Added 29.6%
648,000 $36.1 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $24.6 Million - $32.1 Million
500,000 New
500,000 $32.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.